Background: Green tea is widely used by women for the prevention and treatment of breast cancer. The authors aimed to determine the efficacy of green tea ingestion on the risk of breast cancer development and the risk of breast cancer recurrence. Methods: The authors conducted a systematic review and meta-analyses of observational studies from systematic searches of 8 electronic data sources and contact with authors. They included studies assessing breast cancer incidence and recurrence. Results from cohort studies and case-control studies were pooled separately using a random effects model with testing of a priori hypotheses to explain heterogeneity. Results: The pooled relative risk (RR) of developing breast cancer for the highest levels of green tea consumption in cohort studies was 0.89 (95% confidence interval [CI], 0.71-1.1; P = .28; I 2 = 0%), and in case control studies, the odds ratio was 0.44 (95% CI, 0.14-1.31; P = .14; I 2 = 47%). The pooled RR of cohort studies for breast cancer recurrence in all stages was 0.75 (95% CI, 0.47-1.19; P = .22; I 2 = 37%). A subgroup analysis of recurrence in stage I and II disease showed a pooled RR in cohort studies of 0.56 (95% CI, 0.38-0.83; P = .004; I 2 = 0%). Dose-response relationships were evident in only 3 of the 7 studies. Conclusion: To date, the epidemiological data indicates that consumption of 5 or more cups of green tea a day shows a non-statistically significant trend towards the prevention of breast cancer development. Evidence indicates that green tea consumption may possibly help prevent breast cancer recurrence in early stage (I and II) cancers. However, conclusions as to the potential therapeutic application of green tea are currently impossible to make due to the small number of studies conducted, the lack of any clinical trial evidence, the lack of a consistent dose-response relationship, and the potential for interaction with standard care.
The use of green tea (Camellia sinensis) as a traditional cancer treatment has a long history in Asian cultures.
The use of green tea as an adjunct cancer therapy in Western culture is increasing, possibly due to a growing enthusiasm for complementary therapies to combat cancer. 1 Background information on green tea is provided in Table 1 .
Numerous animal and in vitro studies have explored the mechanisms of green tea's potential anticancer activity. In vitro studies have demonstrated that the green tea catechins, especially epigallocatechin gallate (EGCG), have antioxidant properties, [2] [3] [4] [5] have antiangiogenic properties, [6] [7] [8] [9] [10] suppress neoplastic cell proliferation, 11, 12 inhibit the formation of N-nitroso compounds, 13 inhibit cell division by telomerase inhibition, 14 upregulate intercellular gap junction communication, [15] [16] [17] interfere with estrogen metabolism, 18, 19 and increase apoptosis in cancer cells. [20] [21] [22] [23] [24] The evidence for green tea's use as an anticancer agent from human clinical studies includes several case-control and cohort studies that have shown variable results; some have suggested that green tea consumption may decrease cancer risk, while others report no benefit. [25] [26] [27] [28] [29] To date, no randomized controlled trials have addressed outcomes of green tea consumption on breast cancer. In this article, we synthesize the current epidemiological evidence to determine the effects of green tea consumption on breast cancer incidence and recurrence.
Methods

Literature Search
We searched Medline (1966 ( -November 2004 , AMED (1985 ( -November 2004 , AltHealthWatch (1990 ( -November 2004 , CancerLit (1963 ( -November 2004 , CHKI (Chinese database, inception to October 2004), CinAhl (1982 ( -November 2004 , EMBASE (1980 ( -November 2004 , and the Cochrane Library (inception to November 2004) for relevant studies in all languages. We supplemented this search by reviewing reference sections of relevant articles and by searching for unpublished trials on the National Research Register (United Kingdom; October 1998-November 2004) and Clinical Trials.Gov (February 2000 -November 2004 ). In addition to the systematic database searches, we contacted authors of relevant studies.
Study Selection and Characteristics
Two reviewers (D.S. and P.W.) independently evaluated the abstracts identified by our search. To be included in the final analysis, studies had to use observational or randomized trial designs to examine the effect of green tea consumption on breast cancer incidence or recurrence in men and women of all ages. Studies were excluded if they did not examine green tea's effect in isolation from other teas.
Data Abstraction and Validity Assessment
Two authors (D.S. and P.W.) independently extracted data and appraised the characteristics of the studies. In the case of the Chinese language database, P.W., in consultation with D.S., evaluated and extracted the information from the 1 article retrieved via this database. 30 Population profile, response rate, confounding factors, green tea dosage, and dose-response relationships in the studies were determined by consensus. A third reviewer (E.M.) dealt with any discrepancies as they arose.
Statistics
Kappa scores were calculated to determine chanceadjusted interobserver agreement in the study identification process. We calculated relative risk (RR) for cohort studies and odds ratio (OR) for case-control studies. The outcomes of primary interest were incidence of breast cancer in previously undiagnosed women and recurrence of breast cancer in those with a prior diagnosis. In each of the studies, all dosage levels of green tea were examined to determine if a doseresponse relationship existed. In the final analysis, highest consumption levels were used to determine pooled RRs and ORs. Highest consumption levels were chosen a priori to maximize the likelihood of detecting an association if indeed it was present.
Pooled analysis was conducted using a random effects model. The outcomes of breast cancer incidence and recurrence are clearly disparate and constitute 2 separate populations and dictate 2 separate analyses. We tested for homogeneity using the Zalen test and the I 2 statistic. 31 A priori explanations of heterogeneity include cancer stage (stages I and II vs stages III and IV), study quality, and green tea dosage. Publication bias was tested using both the Egger test with funnel plot and Kendall's test on standardized effect versus variance. StatsDirect was used for all metaanalytic procedures (StatsDirect, Manchester, UK).
Results
The systematic literature search yielded 72 abstracts, of which 10 were identified for further examination and the full articles collected (see Figure 1 ). Three of the 10 studies were excluded: 1 study because it examined catechin consumption rates based on overall diet and catechin excretion and did not look at green tea in isolation, 32 and another because it looked at the incidence of all cancers without isolating the incidence of breast cancer alone 33 (the authors declined to provide breast cancer-specific data), and the third study 34 because it was a follow-up to a study already included in our review 35 (this provided genotype examination of women with breast cancer according to their green Table 1 
. Background Information on Green Tea
Green tea:
Tea made from the dried leaves of Camellia sinensis (L.) Kuntze (Theaceae) is one of the most widely consumed beverages in the world. Approximately 20% of the world's tea is consumed as green tea. Green tea is produced by briefly heating or steaming the shrub's leaves immediately after harvest. This denatures enzymes in the leaves, resulting in minimal oxidation of the herb's naturally occurring polyphenols, commonly referred to as catechins. As well as for its claimed benefit in cardiovascular health, dental health, weight loss, and cognitive function, this herb is used for its purported beneficial effects on cancer. Synonyms:
Camellia sinensis, Thea sinensis L., Camellia assamica (J W Mast) Hung T Chang, Chinese tea, Japanese tea, Gruner tea, green tea extract, GTE, Matsu-cha tea. Source:
Leaves of the perennial shrub Camellia sinensis Constituents: The principal constituents are the flavonol polyphenols, known as catechins: 10%-15% (-)-epigallocatechin-3-gallate, 6%-10% (-)-epigallocatechin, 2%-3% (-)-epicatechin gallate, 2% (-)-epicatechin, 2%-3% caffeine (percentages shown are derived from the dry weight of the leaf). Other constituents include theophylline, theobromine, protein (15%-20%), fiber, sugars (5%), B vitamins, ascorbic acid, Ltheanine, gallic acid, malic acid, oxalic acid, and fats.
tea consumption levels 34 ). Publication bias was assessed, but too few studies were included for a meaningful interpretation of the tests. Thus, 7 studies were included for analysis. The κ value for inclusion of the articles was 1.0, indicating complete agreement between the initial reviewers (D.S. and P.W.). Tables 2, 3 , and 4 display the study characteristics and results. Figure 1 displays the flow diagram of study selection.
Of the 7 studies, 5 were prevention studies that assessed risk of developing initial breast cancer, and 2 studies addressed risk of breast cancer recurrence in relation to green tea consumption. For the 5 that dealt with risk of breast cancer incidence, 3 were cohort studies (N = 115 601; see Table 2 ) 36-38 and 2 were casecontrol studies (n for cases = 857, n for controls = 1519; see Table 3 ). 30, 35 For the 2 studies that assessed the risk of breast cancer recurrence, both were cohort studies (N = 1632; see Table 4 ). 39, 40 The pooled RR of cohort studies examining risk of breast cancer incidence, using a random effects model, is 0.89 (95% confidence interval [CI], 0.71-1.1; P = .28; I 2 = 0%; P = .8; see Figure 2 ). The pooled OR of case-control studies examining risk of breast cancer incidence is 0.44 (95% CI, 0.14-1.31; P = .14; I 2 = 47%; P = .16; see Figure 3 ). The small number of participants in the Tao study 30 who fit the criteria of highest green tea consumption explains the heterogeneity between the case-controls studies.
The pooled RR of all-stage breast cancer recurrence in included cohort studies is 0.75 (95% CI, 0.47-1.19; P = .22; I 2 = 37%; P = .17; see (table 2) • 2 case-control studies examining the risk of breast cancer occurrence in relation to green tea consumption (table 3) • 2 cohort studies examining the risk of recurrence of breast cancer in relation to green tea consumption (table 4) (text continues on page 150) RR of stage I and II breast cancer recurrence in included cohort studies is 0.56 (95% CI, 0.38-0.83; P = .004; I 2 = 0%; P = .9; see Figure 5 ) and 1.31 (95% CI, 0.62-2.79; P = .3; I 2 = 23%; P = .2) for stage III and IV breast cancer recurrence in cohort studies (z test, P = .049). With respect to a dose-response relationship between green tea consumption and risk reduction Figure 2 Meta-analysis of cohort studies examining the risk of breast cancer incidence according to highest consumption of green tea levels (see Table 2 ). Figure 3 Meta-analysis of case-control studies examining the risk of breast cancer incidence according to highest consumption levels of green tea (see Table 3 ).
for both breast cancer development and recurrence, only 3 of the 7 studies demonstrated a positive relationship between increasing dose and reduced risk. In the studies examining prevention of breast cancer, the 3 cohort studies did not show a dose-response trend ( Table 2) ; however, both the case-control studies did demonstrate a positive dose-response relationship ( Table 3) . For the 2 studies looking at risk reduction of Figure 4 Meta-analysis of risk of recurrence of all-stage breast cancer in cohort studies according to highest consumption levels of green tea (see Table 4 ). Figure 5 Meta-analysis of early-stage (I and II) breast cancer recurrence in cohort studies according to highest consumption levels of green tea (see Table 4 ).
breast cancer recurrence, only 1 study demonstrated a dose-response relationship, and this was only for stage II disease (Table 4 ). In the same study by Inoue et al, 40 analysis of stage I disease demonstrated an inverse relationship, with the greater risk reduction being observed at a consumption level of 3 to 5 cups daily rather than at 6 or more cups daily (Table 4 ).
Discussion
This systematic review and meta-analysis offers tentative support that high levels of green tea consumption are positively correlated with prevention of recurrence of early-stage breast cancer but not in the case of more serious disease. The results of our meta-analysis should be interpreted with caution considering the small number of observational studies available. However, the combined data from all the studies do provide enough power to validate the meta-analysis. The pooled analysis does not definitively support the use of green tea in primary prevention of breast cancer; however, a trend toward risk reduction is demonstrated in nearly all the case-control and cohort studies.
There are several limitations to be considered in our meta-analysis. Primarily, no randomized controlled trials have been conducted to date, and only observational studies are available for this review. A principal limitation of the observational studies is the variability of response rate to questionnaires concerning green tea intake. Questionnaire response rate in the cohort studies was highly variable, ranging from 62% to 97%. In the case-control study by Tao et al 30 and the cohort studies by Key et al 37 and Inoue et al, 40 the authors did not account for the important confounding factors of smoking and alcohol consumption. These confounders may have skewed the results, as they are known risk factors in the development of breast cancer. In addition, the cohort study by Inoue et al 40 did not report controlling for the primary treatment the women had undergone for their breast cancer. In all studies, the confounding factors as listed in Tables 2, 3 The major threats to validity in observational studies are the potential for confounding and selection bias that could distort the findings. The statistical combination of these results could therefore produce precise yet unreliable results. 41 Case-control studies are a lower level of evidence than cohort studies and may provide spurious results due to selection bias. In our meta-analysis, the casecontrol studies gave a greater pooled difference than the cohort studies did. The results, however, did not achieve significance when using a random effects model. In a post hoc analysis applying a fixed-effects model, we observed a statistically significant RR of 0.57 (95% CI, 0.38-0.86; P = .007; I 2 = 47%). The larger number of outcomes in the study by Tao et al 30 rather than a smaller number contribute to this limitation, a paradoxical outcome of using the random effects model.
In the case of the 2 studies assessing risk for breast cancer recurrence, the 2 populations have a high degree of homogeneity. Both cohort groups are from urban Japanese hospital outpatient populations and are relatively similar in age range, history of exposure to ionizing radiation, potential biases due to study design, and geographic location. Ultimately, it is unknown if different populations will have a different response to green tea. Therefore, given the similarity of the populations from the 2 studies assessing risk of breast cancer recurrence, the pooled data are viewed with a slightly greater degree of confidence.
The potential for publication bias must also be considered in every systematic review, especially among observational studies. 42 Eggers test and Kendall's τ had too small a sample size to conduct a robust evaluation, yet our search strategy was very broad in terms of the multiple sources accessed as well as the low threshold for retrieval with no language restrictions. Of greatest strength is the inclusion of the CHKD database, a Chinese database encompassing Asian trials that are often excluded from indexing in Western databases. In this case, we identified 1 additional Chinese language cohort study examining breast cancer incidence in relation to green tea consumption. 30 Our subgroup analysis indicates that a high intake of green tea may be associated with a relative risk reduction in stage I and II breast cancer recurrence. However, subgroup analyses should be interpreted with caution, and several criteria should be applied in determining the credibility of the within-study comparisons. 43 Most important, we made the a priori hypothesis to assess cancer stage, thus decreasing the likelihood of a type I error. Overall, we found that the magnitude of the protective effect is larger in stage I and II cancer in comparison to the stage III and IV cancer, with a difference that is statistically significant (P = .049).
Because of the potential inhibitory effect of green tea on angiogenesis and metastasis, [6] [7] [8] there is some rationale and biological plausibility that green tea is more effective in preventing recurrence in less severe stages of the disease. Given the fact that the presence of angiogenesis and metastasis is much rarer, by definition, in early-stage cancer, green tea might effect a reduction in recurrence in the early stages of disease, more so than at a later stage. If metastatic spread has already taken place, the likelihood of a subtle molecular agent having any real effect is remote.
Recently, investigators conducted a systematic review of the evidence for green tea in risk reduction of gastrointestinal cancer. 44 As is the case for green tea and breast cancer, the investigators did not identify any randomized controlled trials. Findings of the gastrointestinal/green tea review demonstrate that green tea is associated with reduced adenomatous polyp formation and reduced risk of chronic atrophic gastritis. With respect to the development of stomach and intestinal cancer, however, the authors found that there is no supportive evidence for green tea consumption as a preventative agent. 44 If there actually is a protective effect, it is difficult to determine what the optimal dose of green tea might be since the methods of tea preparation differ from person to person and study to study. Variables in preparation include but are not limited to steeping time, amount of tea leaves used, the reusing of tea leaves for more than 1 cup of tea, cup size, quality of the tea, freshness of the leaf, and steeping temperature. While most of the studies did not exhibit a dose-response relationship, the optimal effect was achieved at the highest dose in all cases except for stage I breast cancer in the study by Inoue et al. 40 Green tea consumption was measured in a number of ways, with the predominant measure being number of cups. Nearly all the studies indicate greatest risk reduction at consumption levels equal to or more than 5 cups a day. We roughly surmise that any protective effect is most likely to result from exposure to green tea at consumption levels greater than or equal to 5 cups a day.
The results of this review should be of interest as green tea is widely used, has few documented adverse effects, and is relatively inexpensive. An important concern, however, is the possibility for green tea to interact negatively with conventional cancer treatment. One pharmacokinetic clinical trial examining green tea's impact on cytochrome P450 3A4 found no significant interaction with the probe drugs dextromethorphan and alprazolam. 45 Green tea has antioxidant properties, and as such, there is a concern that it may interfere with the activity of chemotherapy and radiation therapy. [46] [47] [48] [49] However, there is also evidence that some antioxidants can enhance the effect of chemotherapeutic agents. [50] [51] [52] With regard to green tea, a single in vitro study implies that green tea may promote tumor survival pathways associated with hypoxia-inducible factor-1 that are targeted by some chemotherapies. 53 Another consideration is the potential for antioxidants and specifically green tea to reduce the cytotoxicity of chemotherapy. 54 Evidence also exists to support green tea and specifically the catechin EGCG as reducing the negative effects of ionizing radiation without curtailing benefit. 55 In summary, our systematic review and meta-analysis did not find a significant effect of green tea on breast cancer prevention. Green tea consumption, however, may be associated with a reduced risk of recurrence of stage I and II breast cancer. Given the encouraging findings of this review for prevention of breast cancer recurrence, randomized controlled trials are warranted to show any true causality.
In women recovering from breast cancer who are receiving conventional treatment, green tea should be used with some caution as the interactions of green tea with standard treatment such as chemotherapy or hormonal therapy have not been fully defined. Investigators should consider organizing, and granting agencies supporting, both clinical trials examining interactions between green tea and conventional treatments for breast cancer and randomized trials looking at the impact of green tea on early breast cancer recurrence.
